News
03-16-2011, 04:24 AM
ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, has signed an outsource research service agreement with Shenogen Pharma Group to develop therapeutic monoclonal antibodies targeting the ER-alpha 36 receptor for cancer treatment.
More... (http://www.news-medical.net/news/20110316/Shanghai-ChemPartner-signs-outsource-research-service-agreement-with-Shenogen-Pharma.aspx)
More... (http://www.news-medical.net/news/20110316/Shanghai-ChemPartner-signs-outsource-research-service-agreement-with-Shenogen-Pharma.aspx)